Chronic insomnia and CSF markers of dementia - Phase 2

Brief description of study

The longstanding view has been that insomnia, and other forms of sleep disturbance, emerge as a consequence of dementia and are the result of progressive neuronal damage. However, there is growing evidence that the direction of causation may go both ways, with sleep disturbance potentially increasing vulnerability to dementia. Longitudinal studies have found that sleep disturbance often precedes and increases risk for dementia by several years.The purpose of this study is to examine the relationship between chronic insomnia and dementia biomarkers and orexin levels found in cerebrospinal fluid (CSF).

Fifteen adults age 30-50 with chronic insomnia will undergo overnight polysomnography and CSF sampling in the morning as part of protocol number 829221 (may viewed here: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/5995/dementia-insomnia-chronic-insomnia-and-csf-markers-of-dementia/).

Participants who wish to enroll in phase 2 must first have been enrolled in phase 1 linked above.

Cognitive behavioral therapy for insomnia (CBT-I) has been the ‘gold standard’ for the treatment of insomnia. Subjects who enroll in phase 2 will receive 6-8 sessions of CBT-I over a 6-8 week timeframe prior to completing a second overnight PSG and and CSF sampling in the morning (again, described in the previous protocol which may be viewed here: https://clinicalresearch.itmat.upenn.edu/clinicaltrial/5995/dementia-insomnia-chronic-insomnia-and-csf-markers-of-dementia/).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    insomnia,dementia
  • Age: Between 30 Years - 50 Years
  • Gender: All


Updated on 18 Aug 2023. Study ID: 833798

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center